The trials conducted on 90 people located in home-like conditions with someone who has symptomatic COVID-19 began on Nov. 12 and will continue until March 2023, the registry's website said.
EU officials discussed procuring Covid-19 drugs at a meeting last week, the EU source said, stressing the bloc of 27 member states wanted to move as fast as possible to buy new treatments but wanted to have further guarantees on their safety.
If cleared, Merck's drug - molnupiravir - would be the first pill shown to treat COVID-19, a potentially major advance in efforts to fight the pandemic. All COVID-19 therapies now authorized in the U.S. require an IV or injection.
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
